Kronos Bio is developing new cancer treatments with a focus on dysregulated transcription factors. Its lead drug candidate, ENTO, is an orally-administered inhibitor for acute myeloid leukemia patients. The company also has another drug, KB-0742, in phase 1/2 clinical trials for treating MYC-amplified solid tumors.